Syncom Formulations India Ltd vs Vivanza Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Syncom Formulations (India) Ltd is ₹ 14.06 as of 05 May 15:30 . The P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Vivanza Biosciences Ltd changed from 227.3 on March 2022 to 687.4 on March 2021 . This represents a CAGR of 24.77% over 5 years The Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Vivanza Biosciences Ltd changed from ₹ 75.46 crore on March 2022 to ₹ 52.24 crore on March 2021 . This represents a CAGR of -7.09% over 5 years The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The revenue of Vivanza Biosciences Ltd for the Dec '25 is ₹ 45.33 crore as compare to the Sep '25 revenue of ₹ 55.37 crore. This represent the decline of -18.13% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The ebitda of Vivanza Biosciences Ltd for the Dec '25 is ₹ 0.29 crore as compare to the Sep '25 ebitda of ₹ 0.61 crore. This represent the decline of -52.46% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The net profit of Vivanza Biosciences Ltd changed from ₹ 0.27 crore to ₹ 0.2 crore over 7 quarters. This represents a CAGR of -15.76% The Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Vivanza Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

About Vivanza Biosciences Ltd

Vivanza Biosciences Limited, formerly known as Ivee Injectaa Limited was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992.
Due to recessionary trends which lead to difficult business conditions in year 1999-2000, the parenteral industry suffered a setback and due to this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015. The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.
It is presently engaged in the business of Pharmaceutical Products. Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.

FAQs for the comparison of Syncom Formulations (India) Ltd and Vivanza Biosciences Ltd

Which company has a larger market capitalization, Syncom Formulations (India) Ltd or Vivanza Biosciences Ltd?

Market cap of Syncom Formulations (India) Ltd is 1,296 Cr while Market cap of Vivanza Biosciences Ltd is 8 Cr

What are the key factors driving the stock performance of Syncom Formulations (India) Ltd and Vivanza Biosciences Ltd?

The stock performance of Syncom Formulations (India) Ltd and Vivanza Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Syncom Formulations (India) Ltd and Vivanza Biosciences Ltd?

As of May 5, 2026, the Syncom Formulations (India) Ltd stock price is INR ₹13.79. On the other hand, Vivanza Biosciences Ltd stock price is INR ₹2.0.

How do dividend payouts of Syncom Formulations (India) Ltd and Vivanza Biosciences Ltd compare?

To compare the dividend payouts of Syncom Formulations (India) Ltd and Vivanza Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.